Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.

Although the study did not meet its primary endpoint of PFS in the intention-to-treat (ITT) population, it has been observed a favorable PFS impact of atezolizumab in the subgroup of patients with PD-L1-positive (or with TILs ≥ 5%) tumors, along with a positive trend in terms of OS advantage [ 31 ].

also in 11,005 other papers